SCHEMBL4997975

SCHEMBL4997975

O=C1Nc2cc(Br)ccc2C1C1Nc2ccccc2/C1=N\O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK2 Q92630 1/20 0.52
MAPK1 P28482 2/20 0.38
CYP1A2 P05177 1/20 0.38
MAPT P10636 3/20 0.36
TP53 P04637 2/20 0.36
POLB P06746 1/20 0.36
AGTR1 P30556 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
EDNRB P24530 1/20 0.33
EDNRA P25101 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
GABRB2 P47870 1/20 0.33
LMNA P02545 1/20 0.33
NQO2 P16083 1/20 0.33
LRRK2 Q5S007 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20682565 0.86 DYRK2 (0.50) DYRK2MAPTKDM4EALDH1A1
SCHEMBL16986622 0.84 CYP1A2 (0.42) DYRK2MAPK1CYP1A2MAPTTP53
SCHEMBL15636520 0.79 DYRK2 (0.47) DYRK2CYP1A2MAPTTP53MEN1
SCHEMBL18466113 0.79 DYRK2 (0.47) DYRK2CYP1A2MAPTMEN1KMT2A
SCHEMBL20402831 0.79 DYRK2 (0.47) DYRK2MAPTTP53KDM4E
SCHEMBL16668782 0.74 CMA1 (0.43) MAPK1CYP1A2MAPTTP53POLB
SCHEMBL21067503 0.74 TP53 (0.47) MAPK1CYP1A2MAPTTP53POLB
SCHEMBL23752444 0.74 MAPT (0.44) DYRK2MAPK1CYP1A2MAPTTP53
SCHEMBL14554226 0.71 MAPT (0.38) MAPK1CYP1A2MAPTTP53POLB
SCHEMBL9899341 0.68 IDO1 (0.45) MAPTLMNALRRK2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11446398-B2 Regulated biocircuit systems OBSIDIAN THERAPEUTICS, INC. (US) 2022-09-20 US disclosed
US-20210254056-A1 IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS CAMP4 THERAPEUTICS CORPORATION 2021-08-19 US disclosed
US-20190247396-A1 DENTAL TREATMENT KING'S COLLEGE LONDON (GB) 2019-08-15 US disclosed
US-20190192691-A1 REGULATED BIOCIRCUIT SYSTEMS OBSIDIAN THERAPEUTICS, INC. 2019-06-27 US disclosed
WO-2018073599-A1 DENTAL TREATMENT KING'S COLLEGE LONDON (GB) 2018-04-26 WO disclosed
EP-2511844-A2 Advanced drug development and manufacturing Los Alamos National Security, LLC (US) 2012-10-17 EP disclosed
EP-2084519-B1 X-RAY FLUORESCENCE ANALYSIS METHOD LOS ALAMOS NAT SECURITY LLC (US) 2012-08-01 EP disclosed
US-20080220441-A1 Advanced drug development and manufacturing THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190247396-A1 DENTAL TREATMENT GSK3B, GSK3A, GSKIP DYRK2 838/4885MAPK1 568/4885CYP1A2 3388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.